title: The role of 18F-fluorodeoxyglucose positron emission tomography in cancer screening - a preliminary report.
abstract: Positron emission tomography (PET) with 18F-fluoro-2 deoxy-D-glucose (FDG) is a non-invasive method for surveying the whole body and detecting various malignancy. A total of 299 subjects underwent whole-body FDG PET studies in our PET center over an 18-month period. FDG PET accurately detected malignant tumors in 7 (2.34%) subjects. False positive FDG PET studies in 3 (1%) subjects and false negative FDG PET studies in 2 (0.6%) subjects were found. Because of the high cost of FDG PET examination, it might not be suitable as a cancer screening test for the general population. However, it is a valuable supplemented tool for routine check-up, particularly for those at high-risk of developing cancer.
authors.affiliation: Department of Nuclear Medicine, China Medical College Hospital, Taichung 404, Taiwan. kaoch5288@sinamail.com
authors.forename: C H
authors.initials: CH
authors.lastname: Kao
authors.forename: A S
authors.initials: AS
authors.lastname: Kwan
authors.forename: J K
authors.initials: JK
authors.lastname: Kwan
authors.forename: M J
authors.initials: MJ
authors.lastname: Chow
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005188:False Negative Reactions; D005189:False Positive Reactions; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008297:Male; D008403:Mass Screening; D008875:Middle Aged; D009369:Neoplasms / Q000000981:diagnostic imaging*; D010865:Pilot Projects; D019275:Radiopharmaceuticals; D014055:Tomography, Emission-Computed
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18